Irinotecan liposòmic pegilat en combinació per al tractament del càncer de pàncrees metastàtic en progressió a gemcitabina
Abstract
Pancreatic cancer is one of the most aggressive and with less percentage of healing. In Europe, pancreatic cancer is the seventh most frequent cancer, representing 2.9% in men and 3.2% in women. It is also the fifth most important cause of death for cancer in Europe (1) (2). The diagnosis is rare before age 45. In 80% of cases it occurs in ages between 60 and 80 years. It has a high mortality rate, mainly due to the fact that most patients (> 50%) have a metastatic disease diagnosis, with a median survival of only 7-11 months. 30% -40% of patients have localized but not resectable disease surgically, with
survival of 11-18 months. The survival rate for the first year is low, around 11-28% and less than 6% survive at 5 years. The purpose of the treatment is palliative to achieve improvements in symptomatology and the quality of life of the patients and extend their survival (2). Three types of pancreatic cancer are described: infiltrating ductal adenocarcinoma, carcinoma of acinar cells and pancreatoblastoma (mainly in children). Adenocarcinoma is the most frequent subtype (> 90%)
Keywords
Pegylated liposomal irinotecan; Gemcitabine; Metastatic pancreatic cancer
Bibliographic citation
Programa d'harmonització farmacoterapèutica. Irinotecan liposòmic pegilat en combinació per al tractament del càncer de pàncrees metastàtic en progressió a gemcitabina. Barcelona: Servei Català de la Salut; 2019.
Audience
Professionals
Use this identifier for quote and/or link this document
https://hdl.handle.net/11351/4171This item appears in following collections
The following license files are associated with this item: